Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily

As reported by Investor's Business Daily

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Investor's Business Daily ↗

Market Samachar is a news aggregator. This article was originally published by Investor's Business Daily. Tap the button above to read the full story on their site.

COMPANIES Tata Motors launches tender offer for Iveco Group; deal values company at €3.82 billion Stocks-Markets-Economic Times
GLOBAL I don't volunteer at my daughter's school. It's better for both of us. businessinsider.com
INDIAN Stocks to watch | LIC gets RBI approval to acquire up to 9.99% stake in ICICI Bank mint - markets
COMPANIES FIIs are coming back: Can Indian stocks sustain buying for 3rd consecutive month in September? Stocks-Markets-Economic Times
INDIAN India vs Pakistan Women Live Streaming: When And Where To Watch IND-W v PAK-W, Women's Asia Cup 2026 NDTV Profit - Latest
INDIAN TCS' HyperVault Secures 264 Acres For Massive 1GW AI Data Center Campus In Hyderabad NDTV Profit - Latest
INDIAN Bethlehem Kudumba Unit Box Office Collection Day 15: Nivin Pauly Starrer Shows Strong Growth In Third Week NDTV Profit - Latest
INDIAN Sam Altman, Dario Amodei Could Face 20 Years In Jail Under Bernie Sanders’ New AI Bill Proposal NDTV Profit - Latest

Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily

More from Market Samachar